S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:NURO

NeuroMetrix Stock Competitors

$9.06
+0.06 (+0.67 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.90
$9.70
50-Day Range
$8.62
$16.51
52-Week Range
$1.47
$38.75
Volume963,245 shs
Average Volume3.56 million shs
Market Capitalization$51.00 million
P/E RatioN/A
Dividend YieldN/A
Beta3.05

NeuroMetrix (NASDAQ:NURO) Vs. TELA, LQDA, TMDI, NMRD, TTOO, STIM, BWAY, PYPD, KRMD, and VERO

Should you be buying NeuroMetrix stock or one of its competitors? The main competitors of NeuroMetrix include TELA Bio (TELA), Liquidia (LQDA), Titan Medical (TMDI), Nemaura Medical (NMRD), T2 Biosystems (TTOO), Neuronetics (STIM), BrainsWay (BWAY), PolyPid (PYPD), Repro Med Systems (KRMD), and Venus Concept (VERO). These companies are all part of the "surgical & medical instruments" industry.

NeuroMetrix vs.

NeuroMetrix (NASDAQ:NURO) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

NeuroMetrix received 127 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 71.72% of users gave NeuroMetrix an outperform vote while only 66.53% of users gave Liquidia an outperform vote.

CompanyUnderperformOutperform
NeuroMetrixOutperform Votes
284
71.72%
Underperform Votes
112
28.28%
LiquidiaOutperform Votes
157
66.53%
Underperform Votes
79
33.47%

Liquidia has a consensus target price of $5.00, suggesting a potential upside of 42.05%. Given Liquidia's higher possible upside, analysts clearly believe Liquidia is more favorable than NeuroMetrix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroMetrix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Liquidia
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

6.0% of NeuroMetrix shares are owned by institutional investors. Comparatively, 20.5% of Liquidia shares are owned by institutional investors. 7.0% of NeuroMetrix shares are owned by insiders. Comparatively, 29.5% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NeuroMetrix has higher revenue and earnings than Liquidia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroMetrix$7.38 million6.91-$2.09 millionN/AN/A
Liquidia$740,000.00247.23-$59.76 million-$1.76-2.00

Liquidia has a net margin of 0.00% compared to NeuroMetrix's net margin of -14.30%. NeuroMetrix's return on equity of -19.02% beat Liquidia's return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroMetrix -14.30% -19.02% -13.50%
Liquidia N/A -71.68% -51.35%

In the previous week, NeuroMetrix had 1 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for NeuroMetrix and 4 mentions for Liquidia. NeuroMetrix's average media sentiment score of 0.61 beat Liquidia's score of 0.42 indicating that NeuroMetrix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroMetrix
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Liquidia
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

NeuroMetrix has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Summary

NeuroMetrix beats Liquidia on 9 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NURO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NeuroMetrix (NASDAQ:NURO) vs. Its Competitors

TypeNeuroMetrixSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
P/E Ratio-33.5692.2129.7727.76
Net Margins-14.30%-469.87%-3,871.70%-1,242.37%

NeuroMetrix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TELA
TELA Bio
2.6181 of 5 stars
$12.70
+0.8%
$19.00
+49.6%
-21.3%$183.79M$18.21M-5.77108Positive News
Gap Up
LQDA
Liquidia
1.8798 of 5 stars
$3.52
+9.1%
$5.00
+42.0%
N/A$182.95M$740,000.00-3.1451Analyst Downgrade
Gap Up
TMDI
Titan Medical
1.5798 of 5 stars
$1.50
+0.0%
$4.00
+166.7%
+94.8%$166.69M$20M-3.499Short Interest ↓
News Coverage
NMRD
Nemaura Medical
2.0333 of 5 stars
$5.92
+1.5%
$17.00
+187.2%
+45.4%$137.98MN/A-16.4425Short Interest ↓
Positive News
TTOO
T2 Biosystems
1.7598 of 5 stars
$0.82
+0.9%
$2.91
+255.1%
-37.8%$136.04M$18.13M-2.73148Positive News
STIM
Neuronetics
2.5848 of 5 stars
$5.04
+3.6%
$15.00
+197.6%
-22.2%$132.64M$49.24M-5.20126
BWAY
BrainsWay
1.8981 of 5 stars
$7.87
+0.8%
$14.00
+77.9%
+30.0%$129.48M$22.06M-34.22100Short Interest ↓
PYPD
PolyPid
1.8583 of 5 stars
$7.40
+1.5%
$19.00
+156.8%
-44.4%$126.14MN/A-4.1367
KRMD
Repro Med Systems
2.3581 of 5 stars
$2.75
+4.4%
$4.25
+54.5%
-54.7%$122.41M$24.18M-39.28101
VERO
Venus Concept
2.6333 of 5 stars
$2.00
+2.5%
$4.63
+131.3%
-25.6%$108.29M$78.01M-2.94384Positive News
Gap Up
High Trading Volume
LYRA
Lyra Therapeutics
1.9315 of 5 stars
$7.91
+0.8%
$26.00
+228.7%
-40.3%$102.84MN/A-3.3038
PDEX
Pro-Dex
1.6181 of 5 stars
$25.90
+0.8%
N/A-4.9%$94.33M$38.03M23.13119Short Interest ↓
Gap Down
NVNO
enVVeno Medical
1.3115 of 5 stars
$9.75
+2.6%
N/A+2,492.0%$84.68M$30,000.00-1.2919
LNSR
LENSAR
2.0381 of 5 stars
$7.53
+0.1%
$20.00
+165.6%
-19.6%$82.51M$26.38M-3.0735News Coverage
FEMY
Femasys
1.4998 of 5 stars
$6.99
+0.1%
$16.73
+139.3%
N/A$82.48MN/A0.0025
IONM
Assure
0.125 of 5 stars
$6.80
+2.9%
N/AN/A$80.49M$3.52M-17.00N/A
NEPH
Nephros
2.325 of 5 stars
$7.65
+1.4%
$13.83
+80.8%
+18.5%$78.16M$8.56M-20.1327
AVGR
Avinger
1.6331 of 5 stars
$0.76
+2.6%
$2.50
+229.1%
+162.1%$72.43M$8.76M-2.9272Gap Up
DCTH
Delcath Systems
1.9514 of 5 stars
$9.61
+2.1%
$24.00
+149.7%
-18.0%$70.69M$1.16M-2.5536
SRTS
Sensus Healthcare
2.0914 of 5 stars
$4.00
+0.3%
$6.33
+58.3%
+40.0%$66.48M$9.58M-30.7742Positive News
SSKN
STRATA Skin Sciences
2.0381 of 5 stars
$1.88
+2.1%
$3.00
+59.6%
+56.1%$64.61M$23.09M-20.89109
AEMD
Aethlon Medical
1.7848 of 5 stars
$3.39
+1.2%
$10.00
+195.0%
+105.4%$52.16M$660,000.00-5.148Short Interest ↑
NVCN
Neovasc
1.7848 of 5 stars
$0.71
+4.1%
$2.00
+180.3%
-72.8%$48.22M$1.96M-0.8371Short Interest ↓
INVO
INVO Bioscience
1.7581 of 5 stars
$4.19
+5.3%
$5.25
+25.3%
-3.2%$43.87M$1.04M-3.0410Positive News
Gap Up
SINT
Sintx Technologies
1.6331 of 5 stars
$1.26
+0.8%
$2.75
+118.3%
-32.8%$31.13M$590,000.000.0032News Coverage
DYNT
Dynatronics
0.8265 of 5 stars
$1.51
+0.7%
N/A+117.1%$30.91M$53.41M-5.39193
MOTS
Motus GI
1.7314 of 5 stars
$0.61
+2.6%
$1.85
+203.8%
-33.9%$29.37M$100,000.00-1.0124
SIGY
Sigyn Therapeutics
0.3333 of 5 stars
$0.75
+6.7%
N/AN/A$27.50M$30,000.000.002Gap Down
NVIV
InVivo Therapeutics
1.0848 of 5 stars
$0.64
+0.0%
N/A-52.7%$21.93MN/A0.006
RMED
Ra Medical Systems
1.6915 of 5 stars
$3.07
+0.7%
$7.00
+128.0%
-53.0%$21.58M$4.41M-0.2985News Coverage
PSTV
Plus Therapeutics
1.8865 of 5 stars
$1.71
+2.3%
$7.00
+309.4%
-34.7%$20.67M$300,000.00-1.012,018Upcoming Earnings
IINN
Inspira Technologies Oxy B.H.N.
1.825 of 5 stars
$2.44
+0.8%
$9.00
+268.9%
N/A$19.02MN/A0.00N/APositive News
Gap Down
APOP
Cellect Biotechnology
0.9598 of 5 stars
$15.07
+5.0%
N/A+77.3%$14.72MN/A0.002,020
GMVD
G Medical Innovations
0 of 5 stars
$2.33
+2.1%
N/AN/A$0.00N/A0.00N/A
This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.